

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended September 30, 2021

Names of related parties where there are transactions and description of relationships**a Key Management Personnel (KMP)**

Mr. Dilip Shantilal Shanghvi	Managing Director (DIN: 00005588)
Mr. Israel Makov	Chairman and Non- Executive Director (Non- Independent) (DIN : 05299764)
Mr. Kalyanasundaram Iyer Natesan Subramanian	Wholetime Director (DIN : 00179072)
Mr. Sailesh Trambaklal Desai	Wholetime Director (DIN: 00005443)
Mr. Sudhir Vrundavandas Valia	Non-Executive and Non-Independent Director (DIN : 00005561)

b Relatives of Key Management Personnel

Mr. Aalok Shanghvi
Ms. Vidhi Shanghvi

c Others (Entities in which the KMP and Relatives of KMP have control or significant influence)

Airamatrix Private Limited
Alfa Infraprop Private Limited
Fortune Integrated Assets Finance Ltd
Kism Textiles Private Limited
Makov Associates Limited
Shanghvi Finance Private Limited
Sidmak Laboratories (India) Private Limited
Sun Petrochemicals Private Limited
Sun Pharma Advanced Research Company Limited
United Medisales Private Limited

d Joint Venture

Artes Biotechnology GmbH

e Associates

Intact Solution LLC
Medinstill LLC
Medinstill Development LLC
Tarsier Pharma Ltd (Formerly known as Tarsius Pharma Ltd.)

f Unconsolidated Subsidiary

Foundation for Disease Elimination and Control of India

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended September 30, 2021

Transactions during half year ended September 30, 2021 with related parties :	Rs. In Million
	Half Year ended September 30, 2021
Purchase of goods	137.7
Others	137.7
Revenue from contracts with customers, net of returns	109.4
Others	109.4
Sale of property, plant and equipment and other intangible assets	3.9
Others	3.9
Other operating revenue /Other income	6.9
Others	6.9
Receiving of service	1,088.2
Others	1,088.2
Reimbursement of expenses (Paid)	22.4
Joint venture	0.0
Others	22.4
Rendering of service	144.9
Others	144.9
Reimbursement of expenses (Received)	27.5
Others	27.5
Deposit Received	0.9
Others	0.9
Loan given	1,080.9
Associate *	1,073.2
Joint venture	7.7
Interest Income	0.1
Joint venture	0.1
Investment in Associate	151.9
Associate	151.9
Lease Rental and hire charges (Income)	15.6
Others	15.6
Rent expense / Payment towards Lease Liabilities	4.8
Others	4.8
Remuneration/ compensation	174.5
Key management personnel	141.6
Relatives of Key management personnel	32.9
Donation	2.7
Unconsolidated subsidiary	2.7

* Includes conversion of Advance (capital advance and advance towards supply of goods/services) to Loan (convertible note).

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Related Party disclosure on a consolidated basis - Half year ended September 30, 2021

Balance outstanding as at end of the period	
	As at September 30, 2021
Receivables	214.9
Others	214.9
Unconsolidated subsidiary	0.0
Payables	1,126.9
Others	1,032.4
Joint venture	0.1
Key management personnel	94.4
Security deposit received	0.9
Others	0.9
Security deposit given	0.5
Others	0.5
Loan given	1,454.2
Associate	1,446.5
Joint venture	7.7
Interest Receivable	0.1
Joint venture	0.1
Lease liability	71.0
Others	71.0
Advance from customer	0.9
Others	0.9
Advance (Includes capital and supply of goods/services)	211.2
Associates	211.2

NOTE :

- 1 Drawn in accordance with applicable accounting standards for the period Half year ended September 2021.
- 2 Key management Personnel (KMP) and Relatives of KMP who are under the employment of the Company are entitled to post employment benefits and other long term employee benefits recognised as per Ind AS 19 - 'Employee Benefits'. As these employee benefits are lump sum amount provided on the basis of actuarial valuation, the same is not included above and there is no Share-based payments to key management personnel and relatives of KMP.